Axovant Sciences (AXON) Lowered to Hold at Jefferies Group

Jefferies Group downgraded shares of Axovant Sciences (NASDAQ:AXON) from a buy rating to a hold rating in a research note released on Thursday, MarketBeat.com reports. Jefferies Group currently has $6.00 price target on the biotechnology company’s stock.

Other research analysts have also issued reports about the stock. Oppenheimer reissued a buy rating and set a $30.00 price target on shares of Axovant Sciences in a research report on Monday, September 25th. HC Wainwright reissued a buy rating and set a $11.00 price target on shares of Axovant Sciences in a research report on Wednesday, September 27th. BidaskClub raised shares of Axovant Sciences from a sell rating to a hold rating in a research report on Thursday, October 5th. Robert W. Baird reissued a hold rating and set a $6.00 price target on shares of Axovant Sciences in a research report on Wednesday, November 1st. Finally, Zacks Investment Research lowered shares of Axovant Sciences from a buy rating to a hold rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $14.18.

Axovant Sciences (NASDAQ:AXON) opened at $4.97 on Thursday. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 12-month low of $4.60 and a 12-month high of $27.98. The firm has a market cap of $555.78, a PE ratio of -2.16 and a beta of 0.06.

A number of hedge funds have recently made changes to their positions in the business. FMR LLC raised its position in shares of Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after purchasing an additional 6,558,462 shares during the period. Capital Research Global Investors raised its position in shares of Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Axovant Sciences in the second quarter valued at approximately $47,854,000. OxFORD Asset Management LLP raised its position in shares of Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares during the period. Finally, Eagle Asset Management Inc. bought a new stake in shares of Axovant Sciences in the third quarter valued at approximately $4,471,000. 96.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/12/25/axovant-sciences-axon-lowered-to-hold-at-jefferies-group.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit